摘要
目的探讨血清甲胎蛋白(AFP)、转肽酶Ⅱ(GGTⅡ)、a-l-岩藻糖苷酶(AFU)及去r-羧基凝血酶原(DCP)联合检测在肝癌患者中的诊断价值。方法选择2020年1月至2022年1月湖北医药学院附属十堰市太和医院肝胆胰诊疗中心收治的肝癌患者104例为肝癌组,选择同期治疗的肝硬化患者34例为肝硬化组,选择同期治疗的慢性肝炎患者31例为肝炎组,选择同期健康体检者29名为对照组。采用电化学发光免疫分析测定各组AFP水平,采用全自动生化分析仪测定各组GGTⅡ水平,采用化学比色速率法测定AFU水平,采用酶联免疫吸附试验测定各组DCP水平。绘制ROC曲线,分析血清AFP、GGTⅡ、AFU、DCP及联合测定在肝癌中的诊断效能。结果肝癌组血清AFP、GGTⅡ、AFU、DCP水平高于肝硬化组、肝炎组及对照组,肝硬化组血清GGTⅡ水平高于肝炎组及对照组,肝炎组血清GGTⅡ水平高于对照组,差异均有统计学意义(P<0.05)。肝癌组不同肿瘤直径、肿瘤分期、门静脉癌栓及远处转移病理状态下患者血清AFP、GGTⅡ、AFU、DCP比较具有统计意义(P<0.05)。ROC曲线结果表明:血清AFP、GGTⅡ、AFU、DCP联合检测在肝癌患者中诊断灵敏度与特异度高于四指标单一检测(P<0.05)。结论血清AFP、GGTⅡ、AFU、DCP在肝癌患者中呈高表达,在不同病理中表达水平存在差异,不同指标联合测定能提高诊断灵敏度与特异度。
Objective To investigate the combined detection of serum alpha-fetoprotein(AFP),transpeptidaseⅡ(GGTⅡ),a-l-fucosidase(AFU)and de-r-carboxyprothrombin(DCP)in the diagnosis of liver cancer patients value.Methods From January 2020 to January 2022,104 patients with liver cancer who were admitted to the Hepatobiliary and Pancreatic Diagnosis and Treatment Center of Shiyan Taihe Hospital Affiliated to Hubei University of Medicine were selected as the liver cancer group;34 patients with liver cirrhosis treated during the same period were selected as the liver cirrhosis group;Thirty-one chronic hepatitis patients treated during the same period were selected as the hepatitis group;29 healthy subjects were selected as the control group.Electrochemiluminescence immunoassay was used to determine the level of AFP in each group;automatic biochemical analyzer was used to determine the level of GGTⅡ in each group;AFU level was determined by chemical colorimetric rate method;DCP level in each group was determined by enzyme-linked immunosorbent assay;The ROC curve was drawn,the diagnostic efficacy of serum AFP,GGTⅡ,AFU,DCP and combined assays in liver cancer was analyzed.Results The serum levels of AFP,GGTⅡ,AFU and DCP in the liver cancer group were higher than those in the liver cirrhosis group,hepatitis group and control group(P<0.05).The serum GGTⅡ level in the liver cirrhosis group was higher than that in the hepatitis group and the control group(P<0.05).The level of serum GGTⅡ in the hepatitis group was higher than that in the control group(P<0.05).The comparison of serum AFP,GGTⅡ,AFU and DCP in patients with liver cancer under different tumor diameters,tumor stages,portal vein tumor thrombus and distant metastases was statistically significant(P<0.05).The ROC curve results showed that the combined detection of serum AFP,GGTⅡ,AFU and DCP had higher diagnostic sensitivity and specificity than the single detection of the four indicators in patients with liver cancer(P<0.05).Conclusion Serum AFP,GGTII,AFU and DCP are highly expressed in patients with liver cancer,and there are differences in the expression levels in different pathologies.The combined determination of different indicators can improve the diagnostic sensitivity and specificity.
作者
陈琳
张恒
江斌
CHEN Lin;ZHANG Heng;JIANG Bin(Hepatobiliary Pancreatic Diagnosis and Treatment Center,Taihe Hospital,Shiyan,Hubei,China,442000)
出处
《分子诊断与治疗杂志》
2022年第8期1283-1286,1291,共5页
Journal of Molecular Diagnostics and Therapy
基金
肝胆胰恶性肿瘤研究基金临床研究创新项目(CXPJJH11800001-2018246)。
